Navigation Links
After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
Date:7/11/2013

EXTON, Pa., July 11, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, for late-phase products for chronic kidney disease (CKD) patients—including AbbVie's altrasentan, Concert Pharmaceuticals' CTP-499, Mitsubishi Tanabe's MP-146/AST-120, Fibrogen's FG3019, Pfizer's PF00487791 and PF04634817 and Eli Lilly's LY2382770—the percentage of likely candidates is typically, but not always highest, in Stage 3b and Stage 4. TreatmentTrends: Chronic Kidney Disease Stages 1-5 ND (US) also finds that, among physicians who treat CKD, familiarity with new products in development is low, but interest is generally high after reviewing brief product profiles.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

The report also finds that among 250 surveyed nephrologists, endocrinologists and primary care physicians (PCPs), PCPs are significantly more likely than other physician groups to make the initial diagnosis of CKD, and PCPs account for the majority (51 percent) of the CKD non-dialysis patient referrals that nephrologists receive. Physicians report that CKD patients are most often diagnosed in Stage 3; nephrologists report CKD patients are diagnosed significantly later in the disease process compared with what PCPs and endocrinologists report.

 "Eighty-six percent of physicians believe that the ideal timing for a new CKD agent designed to slow disease progression would be either during treatment of patients with early symptoms or for asymptomatic patients," said BioTrends Research Group Director Rob Dubman. "Given this, these patients are likely to be with the PCP or endocrinologist at that point during the dise
'/>"/>

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. CalHIPSO Enrolls Over 7,700 Providers in EHR Implementation Program, Hits Other Key Milestones After First Two Years
3. Parent Project Muscular Dystrophy Endorses Senate Version of Prescription Drug User Fee Act After Patient Voice Strengthened
4. One Year After TomoTherapy Acquisition, Accuray on Track to Meet or Exceed Integration Success Metrics And Expecting Near-term Return to Profitability
5. Bluechiip Receives First Sales Order from ATCC after Completion of Successful Pilot Trial
6. Makers Of Over-the-Counter Inhaler Leading Fight To Have Product Back On Market After Removal Due To Environmental Treaty
7. Masimo to Report Second Quarter 2012 Financial Results after Market Close on August 1
8. Onyx Pharmaceuticals To Report Second Quarter 2012 Financial Results After Market On August 1, 2012
9. Rheumatoid Arthritis New Major Clinical Target After Mesoblast Obtains Positive Results in Inflammatory Arthritis
10. Lance Armstrong Update: Arrogant Even After Conceding Doping Charges, Asserts Former White House & WADA Spokesman Robert Weiner; Victory for Clean Sport but "Dark Message" Is Science Must Catch Up to Masking Agents Allowing Cheating
11. Protection Against Whooping Cough Waned During the Five Years After Fifth Dose of DTaP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... -- Heska Corporation (Nasdaq: HSKA ) announces the ... Third Quarter 2014 Earnings Conference Call on the WebWhen:Wednesday, ... a.m. (EDT)Where: , www.heska.com (click on the ... of this website)How:Live over the Internet -- Simply log ... you may use the following teleconference access numbers:  Domestic: ...
(Date:10/25/2014)... Oct. 24, 2014   Metanome, Inc. , a ... services and data analysis, was the genomic sequencing provider ... Phase I/II clinical trial of SER 109, an Ecobiotic® ... Clostridium difficile infections (CDI). Metanome has ... R&D and clinical programs. Such genomic characterization has enabled ...
(Date:10/25/2014)... 2014 Best Practices designed the Medical ... a forum for sharing insights about the key ... mechanism for creating and sharing solutions through three ... from the Medical Affairs Consortium survey. ... the first roundtable of the 2014-2015 Medical Affairs ...
Breaking Medicine Technology:Webcast Alert: Heska Announces Third Quarter 2014 Earnings Conference Call Webcast 2Metanome Selected as Metagenomics Provider for Seres Health Clinical Trial 2Strong Participation in Best Practices' Medical Affairs Consortium Survey 2
... , KINGWOOD, Texas , ... (Pink Sheets: IMAI.PK) www.imaiinc.com announced today that ... purchase a minority interest in Assured Pharmacy, Inc. (Pink ... that is focused on selling prescription medications in the ...
... , WEST PALM BEACH, Fla. ... 50+ who have hearing loss, the AARP Hearing Care program, provided by HearUSA ... part of a nationwide rollout. , While one in 10 Americans have hearing ... suffer from this life altering condition. According to the National Institutes of ...
Cached Medicine Technology:International Merchant Advisors, Inc. Signs LOI to Invest in Pharmaceutical Chain 2International Merchant Advisors, Inc. Signs LOI to Invest in Pharmaceutical Chain 3HearUSA Introduces AARP Hearing Care Program for Americans Aged 50-plus in Ohio Today 2HearUSA Introduces AARP Hearing Care Program for Americans Aged 50-plus in Ohio Today 3HearUSA Introduces AARP Hearing Care Program for Americans Aged 50-plus in Ohio Today 4HearUSA Introduces AARP Hearing Care Program for Americans Aged 50-plus in Ohio Today 5
(Date:10/25/2014)... The Wehrman Collaborative, LLC (WeCo) ... disabled users by disabled users, has granted use ... Educational Resources of Burnsville, Minnesota, for their ... the Minnesota Alliance for Patient Safety of Minneapolis, ... website. Both organizations have met WeCo’s Standards ...
(Date:10/25/2014)... Raleigh, NC (PRWEB) October 25, 2014 ... patient who continued to receive pemetrexed (Alimta), after his ... to read the full story , just posted on ... study from Uji Tokushukai Medical Center in Japan suggests ... for mesothelioma patients who cannot tolerate higher ...
(Date:10/25/2014)... FRIDAY, Oct. 24, 2014 (HealthDay News) -- Researchers ... say their findings are cause for concern. ... that are raised for human consumption contribute to ... health, according to background information from the study. ... germs sicken about 2 million people and kill ...
(Date:10/22/2014)... 2014 At a time when the ... and athletes at all levels, the UPMC Sports ... current discussion where two powerful messages are lost: Concussions ... result in full recoveries every day. , In striving ... fact and research, UPMC and the Concussion Program are ...
(Date:10/22/2014)... October 22, 2014 For Dr. Iris Hunter, ... money; it’s an extension of her life’s mission. Her extensive ... as the owner of FirstLight HomeCare, make it clear that ... to me that my work makes a difference in the ... entrepreneurial spirit, so after much research, I felt ready to ...
Breaking Medicine News(10 mins):Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 3Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 3Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 4Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2
... Medical,Inc. (Nasdaq: NXTM ), a leading manufacturer of ... a $50.0 million credit,and security agreement from a group ... Merrill Lynch Business Services Inc., for a term of,42 ... million term loan and a $20.0,million revolving credit facility. ...
... Research Hospital have discovered a new signaling molecule that ... body. The finding could lead to the development of ... such as Type 1 diabetes; and for inflammatory diseases, ... , The St. Jude team discovered that specialized immune ...
... Conn., Nov. 21 Therap Services will host ... 5-7, 2007 in,Southbury, Connecticut. The 2nd Direct Support ... Support Professionals who are daily,users of Therap as ... Therap,s users and its developers and support staff., ...
... survey found , WEDNESDAY, Nov. 21 (HealthDay News) -- Older ... stress, a new study shows. , A team of University ... 53 to 85 who worked at least 20 hours per ... male, 87 percent were white, about 8 percent were black, ...
... Nov. 21 Susan G. Komen for the ... breast cancer research and,community-based outreach programs, is accepting ... who lost a,parent to breast cancer., (Logo: ... Award helps students cover the costs of,tuition, books, ...
... Region activates when a friend,s voice calls, scientists say , ... they,ve spotted a brain region that selectively emphasizes certain sounds, ... person,s name. , Researchers from the University of Washington, Seattle, ... the experimental method they used to detect brain activity associated ...
Cached Medicine News:Health News:NxStage Medical Establishes $50 Million Credit Facility with a Group of Lenders Led by Merrill Lynch Capital 2Health News:NxStage Medical Establishes $50 Million Credit Facility with a Group of Lenders Led by Merrill Lynch Capital 3Health News:St. Jude finds molecule that could improve cancer vaccines and therapy for other diseases 2Health News:St. Jude finds molecule that could improve cancer vaccines and therapy for other diseases 3Health News:Therap Services to Host 2nd Conference for Direct Support Professionals 2Health News:Jobs Don't Stress Most Older Workers 2Health News:Susan G. Komen for the Cure Provides Scholarships for Students Who Lost a Parent to Breast Cancer 2
... 8F Percutaneous Vascular Surgical (PVS) System consists of ... Perclose Knot Pusher. The Prostar XL 8F PVS ... two pairs of sutured needles as well as ... precisely control the needles during deployment. the Perclose ...
... The new solid-state IRIS Medical IQ ... the treatment of retinal disorders and ... represents its latest technological innovation and ... Minimum Intensity Photocoagulation (MIP) procedures in ...
... The AIA-360 is a sophisticated Aumated Immunoassay Analyzer ... analyzer has a footprint of 16 X 16 ... Its compact design is ideal for physician ... testing, such as cardiac panels, as well as ...
... Solitaire represents the latest in green laser ... for use in both the operating room ... preference testing and the most experienced ophthalmic ... is the premium 532nm photocoagulator - unique ...
Medicine Products: